Early after the discovery of FGFR3-TACC3 fusions in human glioma, Di Stefano et al. observed that fusion-positive glioblastomas were highly positive in immunostaining with antibodies targeting the N-terminus of FGFR3 or the C-terminus of TACC3 [76]. The gene discussed is TACC3; the disease is central nervous system cancer.